CLRB - セレクタ・バイオサイエンシ―ズ （Cellectar Biosciences Inc.） セレクタ・バイオサイエンシ―ズCLRBのチャート
CLRBの企業情報
| symbol | CLRB |
|---|---|
| 会社名 | Cellectar Biosciences Inc （セレクタ・バイオサイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Cellectar Biosciences Inc. formerly Novelos Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic PDC''s. The Company''s PDC product portfolio includes CLR 131 which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125 which is for the treatment of micro metastatic disease; CLR 124 which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502 which is for intraoperative tumor margin illumination and non-invasive tumor imaging and CTX Product Portfolio including CLR 1601-PTX CLR 1602-PTX and CLR 1603-PTX product candidates. セレクタ・バイオサイエンシ―ズは米国のバイオ医薬品企業。癌治療薬、癌標的の投影剤の開発に従事。同社の癌注力技術は癌幹細胞を含む癌細胞に対する薬剤の選択的送達を可能にする。開発中の製品候補は、癌標的陽電子放射断層撮影造影剤I-124-CLR1404、癌標的分子放射線治療I-131-CLR1404、非放射光造影剤CLR1502など。 Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company's product pipeline includes one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets. |
| 本社所在地 | 3301 Agriculture Drive Madison WI 53716 USA |
| 代表者氏名 | Stephen Anthony Hill スティーブン・アンソニー・ヒル |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 608-441-8120 |
| 設立年月日 | 35217 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.cellectar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/clrb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.53883 |
| 終値（lastsale） | 2.715 |
| 時価総額（marketcap） | 10311094.875 |
| 時価総額 | 時価総額（百万ドル） 10.21615 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6.03918 |
| 当期純利益 | 当期純利益（百万ドル） -15.39489 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectar Biosciences Inc revenues was not reported. Net loss increased 6% to $6.4M. Higher net loss reflects (Loss)/Gain on revaluation of derivative decrease from $8K (income) to $47K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.73 to -$3.75. |
CLRBのテクニカル分析
CLRBのニュース
Cellectar Biosciences (CLRB) Investor Presentation - Slideshow 2023/03/17 18:43:26 Seeking Alpha
The following slide deck was published by Cellectar Biosciences, Inc.
Cellectar Biosciences GAAP EPS of -$4.05 misses by $0.74 2023/03/09 13:59:44 Seeking Alpha
Cellectar Biosciences press release (CLRB): FY GAAP EPS of -$4.05 misses by $0.74.As of December 31, 2022, the company had cash and cash equivalents of $19.9 million, compared to…
Cellectar Biosciences: Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update 2023/03/09 13:42:00 Finanz Nachrichten
FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization…
Have you been able to find a good deal on Cellectar Biosciences Inc.’s shares? 2023/03/01 16:08:00 US Post News
Cellectar Biosciences Inc. (NASDAQ:CLRB) marked $1.56 per share on Tuesday, up from a previous closing price of $1.50. While Cellectar Biosciences Inc. has overperformed by 4.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLRB fell by -67.49%, with highs and lows ranging from $7.90 to […]
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical 2023/02/15 13:30:00 GlobeNewswire
FLORHAM PARK, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has hired Andrei Shustov, M.D., as its new Senior Vice President, Medical reporting to Mr. James Caruso, president and CEO. In this role, Dr. Shustov will lead and provide oversight on all aspects of the Company’s clinical development program, medical affairs, and medical communications.
Cellectar Biosciences (CLRB) Investor Presentation - Slideshow (NASDAQ:CLRB) 2022/11/04 16:03:22 Seeking Alpha
The following slide deck was published by Cellectar Biosciences, Inc.
Cellectar Biosciences PT Lowered to $25 at Roth Capital 2022/11/03 14:44:01 Investing.com
https://www.investing.com/news/pro/cellectar-biosciences-pt-lowered-to-25-at-roth-capital-432SI-2931444
Recap: Cellectar Biosciences Q3 Earnings 2022/11/03 13:25:24 Benzinga
Cellectar Biosciences (NASDAQ: CLRB ) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:30 AM. Here''s what investors need to know about the announcement. Earnings Cellectar Biosciences missed estimated earnings by 5.79%, reporting … Full story available on Benzinga.com
Cellectar Biosciences GAAP EPS of -$1.28 misses by $0.04 2022/11/03 13:15:05 Seeking Alpha
Cellectar Biosciences press release (CLRB): Q3 GAAP EPS of -$1.28 misses by $0.04.As of September 30, 2022, the company had cash and cash equivalents of $17.8 million, compared to…
Cellectar Biosciences shares dip on $10.7M securities offering 2022/10/21 13:02:02 Seeking Alpha
Cellectar Biosciences (CLRB) shares fell ~18% premarket on announcing concurrent registered direct and private placement offerings of ~$10.7M priced at-the-market under Nasdaq…
Cellectar Biosciences (CLRB) Investor Presentation - Slideshow (NASDAQ:CLRB) 2022/11/04 16:03:22 Seeking Alpha
The following slide deck was published by Cellectar Biosciences, Inc.
Cellectar Biosciences PT Lowered to $25 at Roth Capital 2022/11/03 14:44:01 Investing.com
https://www.investing.com/news/pro/cellectar-biosciences-pt-lowered-to-25-at-roth-capital-432SI-2931444
Recap: Cellectar Biosciences Q3 Earnings 2022/11/03 13:25:24 Benzinga
Cellectar Biosciences (NASDAQ: CLRB ) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:30 AM. Here''s what investors need to know about the announcement. Earnings Cellectar Biosciences missed estimated earnings by 5.79%, reporting … Full story available on Benzinga.com